The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 21, Issue S1, Pages 6-16
Publisher
Wiley
Online
2019-04-19
DOI
10.1111/dom.13691
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial
- (2018) Marja-Riitta Taskinen et al. ATHEROSCLEROSIS
- Macrophages and lipid metabolism
- (2018) Anneleen Remmerie et al. CELLULAR IMMUNOLOGY
- Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial
- (2018) Antonio J. Vallejo-Vaz et al. CIRCULATION
- Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
- (2018) Kausik K. Ray et al. DIABETES OBESITY & METABOLISM
- Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
- (2018) Muhammad Shariq Usman et al. European Journal of Preventive Cardiology
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy
- (2018) Maria Lorenzi et al. Clinical Research in Cardiology
- 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
- (2018) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab Reduces Fatal and Nonfatal Cardiovascular Events
- (2018) Michael Szarek et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Type 2 diabetes in patients with end-stage kidney disease: influence on cardiovascular disease-related mortality risk
- (2018) Wai H Lim et al. MEDICAL JOURNAL OF AUSTRALIA
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
- (2018) Marc P Bonaca et al. Lancet Diabetes & Endocrinology
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk
- (2017) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes
- (2017) Atsushi Shinnakasu et al. Journal of Atherosclerosis and Thrombosis
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- (2017) A. Michael Lincoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
- (2017) Harold E. Bays et al. Journal of the American Heart Association
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
- (2016) Robert S. Rosenson et al. CARDIOVASCULAR DRUGS AND THERAPY
- Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease
- (2016) Børge G. Nordestgaard CIRCULATION RESEARCH
- 9. Cardiovascular Disease and Risk Management
- (2016) DIABETES CARE
- Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up
- (2016) DIABETES CARE
- Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus
- (2016) Masayuki Kaneko et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients
- (2016) Chi-Hung Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- National Lipid Association Annual Summary of Clinical Lipidology 2016
- (2016) Harold E. Bays et al. Journal of Clinical Lipidology
- 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2016) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Approach to diabetes management in patients with CVD
- (2016) Sanam Lathief et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
- (2016) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
- (2016) Lancet Diabetes & Endocrinology
- Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study
- (2016) Jack R W Brownrigg et al. Lancet Diabetes & Endocrinology
- New Insights into the Regulation of Chylomicron Production
- (2015) Satya Dash et al. Annual Review of Nutrition
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study
- (2015) P. C. Deedwania et al. DIABETES OBESITY & METABOLISM
- Pathophysiology of diabetic dyslipidaemia: where are we?
- (2015) Bruno Vergès DIABETOLOGIA
- Association of Cardiometabolic Multimorbidity With Mortality
- (2015) Emanuele Di Angelantonio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010
- (2015) Shona J. Livingstone et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Blood Pressure Lowering in Type 2 Diabetes
- (2015) Connor A. Emdin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C
- (2015) Michael J Pencina et al. European Journal of Preventive Cardiology
- High-density lipoprotein, beta cells, and diabetes
- (2014) A. von Eckardstein et al. CARDIOVASCULAR RESEARCH
- Low Nonfasting Triglycerides and Reduced All-Cause Mortality: A Mendelian Randomization Study
- (2014) M. Thomsen et al. CLINICAL CHEMISTRY
- Triglycerides and cardiovascular disease
- (2014) Børge G Nordestgaard et al. LANCET
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Significance of Silent Myocardial Infarction in Newly Diagnosed Type 2 Diabetes Mellitus
- (2013) Timothy M.E. Davis et al. CIRCULATION
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
- (2013) Francesco Paneni et al. EUROPEAN HEART JOURNAL
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
- (2013) Robert A Hegele et al. Lancet Diabetes & Endocrinology
- Physical Activity and Mortality in Individuals With Diabetes Mellitus
- (2012) Diewertje Sluik et al. ARCHIVES OF INTERNAL MEDICINE
- Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
- (2012) Anders Berg Jørgensen et al. EUROPEAN HEART JOURNAL
- Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
- (2012) Anette Varbo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Gut-liver interaction in triglyceride-rich lipoprotein metabolism
- (2011) Changting Xiao et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men
- (2011) S. Goya Wannamethee et al. ARCHIVES OF INTERNAL MEDICINE
- Fatty Acids, Obesity, and Insulin Resistance: Time for a Reevaluation
- (2011) F. Karpe et al. DIABETES
- What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review
- (2011) M. Chimen et al. DIABETOLOGIA
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
- (2011) M. John Chapman et al. EUROPEAN HEART JOURNAL
- A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia
- (2011) Michael H. Davidson Journal of Clinical Lipidology
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients
- (2011) H. Soran et al. ANNALS OF CLINICAL BIOCHEMISTRY
- Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes
- (2010) Bruno Vergès ATHEROSCLEROSIS
- Postprandial Lipoproteins and Cardiovascular Disease Risk in Diabetes Mellitus
- (2010) Byambaa Enkhmaa et al. Current Diabetes Reports
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- Combination Lipid Therapy in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
- (2009) Kausik K Ray et al. LANCET
- Review of Side-Effect Profile of Combination Ezetimibe and Statin Therapy in Randomized Clinical Trials
- (2008) Amir Kashani et al. AMERICAN JOURNAL OF CARDIOLOGY
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
- (2008) LANCET
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now